Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Beta Drugs Ltd. ( (IN:BETA) ) has issued an announcement.
Beta Drugs Limited has signed a definitive agreement to acquire a 66.09% stake in Nivian Lifesciences Private Limited, a fast-growing Indian branded formulations player focused on in‑vitro fertilisation (IVF) therapies, for INR 69.4 crore, valuing Nivian at INR 105 crore. The deal gives Beta a strong entry platform into the rapidly expanding IVF market, which has grown at about 20% annually and is estimated at INR 1,500–1,700 crore, and is expected to significantly bolster its positioning in women’s health and fertility drugs by combining Beta’s manufacturing strengths with Nivian’s niche IVF product portfolio and marketing capabilities; Nivian’s founder will remain invested and continue to lead the business, supporting continued high growth and deeper market penetration in this segment.
More about Beta Drugs Ltd.
Beta Drugs Limited is a pharmaceutical company focused on branded formulations in complex therapies, including oncology, cosmetology and women’s health, with a growing presence in the Indian fertility drug market. The company leverages strong manufacturing capabilities, cost leadership and deep supplier relationships to strengthen its position in specialized therapeutic segments.
Average Trading Volume: 7,395
Technical Sentiment Signal: Sell
Current Market Cap: 16B INR
For detailed information about BETA stock, go to TipRanks’ Stock Analysis page.